# Checklist: Toxicological Risk Assessment in Practice

## Michael Schwenk and H. Paul A. Illing

### Contents

| Checklist and Comments | 872 |
|------------------------|-----|
| References             | 874 |

#### Abstract

The checklist gives brief practical hints for all those who are occasionally or professionally involved in risk assessment, risk management, and risk regulation. Further details to each topic can be found in the relevant chapters of this book.

M. Schwenk (🖂)

Formerly Medical School, Hannover, Germany e-mail: mike.schwenk@gmx.net

H.P.A. Illing

Centre for Occupational and Environmental Health, University of Manchester, Manchester, UK

Paul Illing Consultancy Services Ltd, Heswall, Wirral, UK e-mail: paul@sherwood37.demon.co.uk

| Checklist  | Comments   |
|--|--|
| Which are the steps of the risk regulation pro-    | ocess?   |
| The IPCS document (IPCS, 1994) identifies          | Risk assessments are made on the basis of                                    |
| these as:  | a scientific examination of toxicity and                                     |
| Risk assessment (in 4 steps):                      | exposure, leading to a risk characterisation.                                |
| Hazard identification                              | The risk management process is aimed at                                      |
| Hazard characterization (including                 | developing an appropriate response to the                                    |
| dose-response relationship)                        | hazard (regulatory, technical, legal). Risk                                  |
| Exposure assessment                                | (or risk-benefit) evaluation, the first step in risk                         |
| Risk characterization                              | management, establishes a qualitative or                                     |
| Risk management                                    | quantitative relationship between risks and                                  |
| Risk evaluation                                    | benefits of exposure to an agent and the                                     |
| Emission and exposure control                      | influence of possible control measures on that                               |
| Risk monitoring                                    | evaluation. It may be necessary to examine                                   |
|  | relative risk and benefit for different agents used                          |
|  | for the same purpose.  |
| What data on toxic properties are needed for       | 1 1  |
| Chemistry  | By proper assessment of the physicochemical                                  |
| Basic physical and chemical properties.            | properties ("insoluble"), it is often possible                               |
| Structure-activity relationships (if available)    | to get a first estimate of the risk level.                                   |
| for the test substance and related substances.     | Data quality (this includes whether appropriate                              |
| Identification of toxic effects                    | protocols and audit procedures were employed)                                |
| Animal testing results (acute, subacute, and       | must be considered. For chemical assessment.                                 |
| chronic toxicity; carcinogenicity; and toxicity to | Klimisch gradings are often used (see Klimisch                               |
| reproduction).                                     | et al. 1997)   |
| Evidence of irritation and sensitization.          | The overall picture will emerge only from the                                |
| Genotoxicity.                                      | sum of all available information.  |
| Results from in vitro tests.                       |  |
| Biochemical mechanism of action.                   | If in doubt, additional information must be asked                            |
|  | from poison control centers and manufacturers.                               |
| Experience in humans.                              | Toxicokinetic data are often ignored in risk assessments – which is a fault. |
| Toxicodynamics                                     | assessments – which is a fault.  |
| Dose-response relationships (size of               |  |
| response).   |  |
| Rates of development and duration of effects.      |  |
| Toxicokinetics                                     |  |
| Absorption rates (oral, inhalation, dermal)        |  |
| Distribution, half-life                            |  |
| Metabolites  |  |
| Routes and rates of elimination                    |  |
| Experience with humans                             |  |
|  | (continued)  |

## **Checklist and Comments**

| What information is provided by the dose-re-  | sponse relationship?   |
|---|--|
| Shows threshold above which effects can be<br>observed (NOAEL/LOAEL/BMD). Large<br>steepness of the dose–response relationship<br>means reduced safety margin. Shape of the<br>curve influences values obtained by<br>extrapolation to low doses (e.g., unit risk).   | Non-sigmoidal dose–response relationship<br>increases the uncertainty in extrapolation to low<br>concentrations.<br>NOAEL values of different studies often differ<br>as they are the dose below the dose at which<br>effects were seen and therefore depend on the<br>dose intervals between doses in the study. They<br>also depend on what parameters were measured<br>in the studies. If in doubt, it should be checked<br>as to whether one of the studies is better suited<br>for a particular risk assessment.                        |
| How is an exposure assessment made?   | I  |
| External exposure<br>Measurement or estimation of the extent of<br>external exposure (in the intake, in the medium<br>[air, water, food basket], or, using more<br>complicated models, in the input to the medium<br>[e.g., water] from the source [e.g., outlet sewer<br>of chemical factory/sewage treatment works]).<br>Observe all routes of exposure (oral,<br>inhalation, dermal).<br>Consider sensitive persons.<br>Internal exposure<br>Calculation of the assumed maximum uptake<br>on the basis of (worst case) scenarios.<br>Probabilistic assessment of the different<br>routes of intake.<br>Measurement of the internal concentration<br>(human biomonitoring). | Exposure estimates can be extremely uncertain.<br>Scenarios (models) should be clearly set out and<br>estimates calculated according to standardized<br>procedures. Estimates should not contain<br>multiple "worst-case" assumptions (if the <i>P</i><br>value of 0.1 [i.e., 1 in 10 will show the effect] is<br>applied three times, this gives a <i>P</i> value of 0.001<br>[1 in 1,000]). Monte Carlo analysis is essential<br>in these circumstances.<br>Human biomonitoring is a very good method for<br>internal exposure assessment. |
| Which safety factors are often used?  |  |
| Usual safety factor for extrapolation for<br>a threshold effect from a good animal data to<br>a general human population = 100 (depends on<br>circumstances).<br>US-EPA and other regulatory agencies<br>often use safety factors up to 10,000<br>(see e.g., IPCS 1994).  | Depending on the size of the selected safety<br>factors, risk assessments can vary enormously<br>even when the experimental data base is<br>identical. This can easily lead to dispute.  |
| Why does epidemiology rarely find a threshol  | d value?   |
| Large uncertainty in the estimation of exposure.<br>Large uncertainty of the effects at low doses.<br>High interindividual variability.   | Lack of thresholds in epidemiological studies<br>may be artificially caused by the multiplication<br>of several uncertainty factors.   |
| Who belong to the vulnerable groups?  |  |
| Pregnant women (organogenesis of the child),<br>infants, and children (organ development,<br>toxicokinetics).<br>Elderly and sick people (low functional<br>reserves, low repair capacity).   | Often, sensitive groups are given special<br>regulatory protection in various laws<br>(occupational safety, baby food, allergens, etc.).<br>This must be considered in the risk management<br>process.   |
| Allergic people (hypersensitivity).   | / .* N   |

What information is provided by the dose-response relationship?

(continued)

| What else must be considered in risk manage   | ment?   |
|---|---|
| Protection philosophy of the respective areas.<br>Guideline values and their rationale. Are they<br>applicable?<br>Verification of measurement results.<br>Quality assurance of the process.  | The safety philosophy may be for good hygiene<br>practice, precautionary, or danger-oriented<br>In order that a risk assessment finds acceptance,<br>it is important to understand the origin of<br>existing regulations as well as the present state<br>of scientific interpretation of the toxicological<br>data.   |
| What does "traffic light principle" mean in re  | egulation   |
| Green: no effect and no action required.<br>Yellow: slightly below threshold level.<br>Adequate action: monitoring.<br>Red: above the threshold of action. Swift action<br>to reduce exposure.  | Multistage systems such as the traffic light<br>system are more flexible. Where only a single<br>limit value exists, a brief or minor overrun may<br>cause action or legal consequences, even if the<br>excess is toxicologically irrelevant.   |
| When is a disease due to toxic substances?  |   |
| Causality can be assumed if exposure levels<br>and exposure duration were sufficient and the<br>response spectrum (the affected organ,<br>expression) characteristic for a compound.<br>The rarer the symptoms occur in daily life,<br>the more secure a causal relationship can be<br>assumed.<br>The criteria to be considered are given in Hill<br>(1965) and are applicable to all toxicological<br>data, not only epidemiological data.  | The causality principle is often presumed for<br>toxic substances. But it is not easy to prove<br>causality. With many drugs, possible unwanted<br>effects are often overlooked. And the dramatic<br>health effects of smoking and alcohol are often<br>socially trivialized and ignored.<br>Some dangerous substances produce very<br>specific disease patterns (e.g., asbestos and<br>mesothelioma).  |
| In which way can the modes of thinking influ  | ence the risk awareness?  |
| Scientific way of thinking ("objective risk")<br>Risk assessment<br>Risk comparison<br>Risk management (technical)<br>Emotional way of thinking by the general<br>public (perceived risk)<br>Risk acceptance<br>Political way of thinking (perceived risk)<br>Risk exaggeration (phantom risk)<br>Risk trivializing<br>Conclusion: understanding the sociological and<br>psychological aspects of risk perception and<br>communication is critical to effective risk<br>management. | Many social groups (toxicologists, engineers,<br>politicians, stakeholders, arbitrator, government<br>representatives, etc.) are potentially involved in<br>risk communication and risk management.<br>In this process, it often happens that different<br>ways of thinking collide. This leads to inner<br>discomfort and confrontation. Knowledge of the<br>various ways of thinking of the general public,<br>as described by psychologists and sociologists,<br>can reduce conflict.<br>A good moderator can help overcome these<br>hurdles.<br>Note: the eloquent charlatan and the lobbyist<br>usually receive more credibility than the highly<br>educated toxicologist and the regulator. |

What else must be considered in risk management?

#### References

- Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300
- IPCS (1994) Assessing human health risks of chemicals: derivation of guidance values for health based limits. Environmental health criteria 170. World Health Organisation, Geneva
- Klimisch HJ, Andreae E, Tillman U (1997) A systematic approach for evaluating the quality of experimental and ecotoxicological data. Regul Toxicol Pharmacol 25:1–5